Replies to post #37139 on RespireRx Pharmaceuticals Inc (RSPI)

[ombowstring]

With a $.5 million/month burn rate (and I don't suspect they've been able to chisel that down significantly), it costs $6 million a year to do nothing. Add in the expense of a clinical trial and they need more money than the current market cap to remain in business.

As I suggested earlier, a financing at these levels is highly unlikely. And as I suggested earlier, a sale of the company for as much as they can get seems to be the best alternative for shareholders. It's almost inconceivable that Cortex can secure enough financing to remain a viable, independent company and move multiple assets forward concurrently, something that a larger company would most likely be able to do. And that would be more beneficial to shareholders than if the company continues to try to limp along on its own.

But we don't even know what options are available to them.

[drfreely]

I think you've outlined all options based on our current limited knowledge of the situation.
#3 is most likely, though it may or may not be with Servier. I guess it comes down to how much
positive data Servier has on the high impacts. Since they are new compounds, there may not be enough data to make them attractive enough.
I suppose it also comes down to what management is willing to part with short of loosing control of the company's future. My guess is that they are currently deferring compensation, and perhaps other expenses to stretch things out as long as possible. Given all the work they've put into this, and having been in similar circumstances in the past, it wouldn't surprise me to see them last until the fall with no financing.
Utilizing another area of expertise, I've noticed that a man down to his last $15 at $5 blackjack table is often the hardest one for the house to crack.